Hospital

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, from the University of Kansas Cancer Center talks about bispecifics and the value of building a network to communicate operationalizing these therapies across clinics.

Renee’ Acosta, RPh, MS, discusses recent developments in the OTC market and key considerations pharmacy staff should prioritize when guiding patients in selecting appropriate over-the-counter therapies.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

Data from COA highlight operationalizing novel therapies in community cancer care.

Pharmacists help prevent communication breakdowns and improve coordination across oncology care teams.

Emerging data regarding newly diagnosed AML found that the Endothelial Activation and Stress Index independently predicts early mortality and ICU admission during intensive induction chemotherapy.

The need for data-driven, multidisciplinary care and the critical role of pharmacists in managing the growing complexity of oncology treatment

Pharmacists are enabling the shift to outpatient bispecific antibody care through education, SOP development, and care coordination.

Harm reduction–based counseling frameworks for cannabis use during pregnancy and lactation can improve patient engagement, disclosure, and safety, with pharmacists playing a key role in implementation.

COA 2026 reveals how bispecific antibodies transform lymphoma care—outpatient workflows, SOPs, and infection vigilance shape safe BTCE delivery.

Postate cancer care shifts toward personalized, team-based management in an increasingly complex therapeutic landscape.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.

Pharmacists are central to implementing bispecific antibody therapies through clinical expertise, operational leadership, and care coordination.

Pharmacists support evidence-based treatment decisions, coordinate multidisciplinary care, and optimize precision oncology outcomes.

Integrated EMR systems and coordinated pharmacy operations can streamline biomarker-driven treatment decisions and improve patient outcomes.

Symptom-based dosing reduced time to medical readiness for discharge compared with scheduled opioid, without increasing short-term safety risks.

Pharmacists play a crucial role in the treatment of patients with chronic myeloid leukemia (CML) taking tyrosine kinase inhibitors.

Pharmacists can help standardize biomarker testing and improve access to targeted therapies in non–small cell lung cancer.

Pharmacists can help optimize TKI therapy in CML through education, adherence support, toxicity monitoring, and collaboration with care teams.

CAR T drives deep remissions in myeloma and lymphoma, but payers, staffing, and hospital partners shape timely community access.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

Cannabis use is common among patients receiving medications for opioid use disorder and is associated with higher rates of anxiety and other comorbid symptoms.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

The once-weekly Saphnelo Pen offers adult patients with systemic lupus erythematosus a new, at-home alternative to monthly intravenous infusions, supported by robust phase 3 data.

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.

This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.